Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Healthtrust
Fuji
Chubb
Cerilliant
Argus Health
Johnson and Johnson
McKesson
QuintilesIMS

Generated: December 11, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ONDANSETRON

« Back to Dashboard

Clinical Trials for Ondansetron

Trial ID Title Status Sponsor Phase Summary
NCT00000289 Role of Metabolites in Nicotine Dependence (3) - 6 Completed University of Minnesota - Clinical and Translational Science Institute Phase 2 The purpose of this study is to determine the effects of various doses of ondansetron transdermal nicotine replacement on tobacco withdrawal symptoms.
NCT00000289 Role of Metabolites in Nicotine Dependence (3) - 6 Completed National Institute on Drug Abuse (NIDA) Phase 2 The purpose of this study is to determine the effects of various doses of ondansetron transdermal nicotine replacement on tobacco withdrawal symptoms.
NCT00000443 Ondansetron Treatment for Alcoholism Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 The purpose of this study is to: a) evaluate the effectiveness of ondansetron (Zofran) in the treatment of alcohol dependent patients; b) investigate whether early versus late onset alcoholism predicts treatment outcome; and c) determine whether the early and late onset groups respond differently to treatment. Individuals will be "typed" into early onset and late onset alcoholism groups. Individuals will be randomly assigned to a 12-week outpatient treatment program.
NCT00004358 Phase II Study of Calcitonin for Tumoral Calcinosis Completed Ann & Robert H Lurie Children's Hospital of Chicago Phase 2 OBJECTIVES: I. Determine whether intermittent, long-term, subcutaneous administration of calcitonin increases phosphaturia, reduces hyperphosphatemia, and increases intact parathyroid hormone levels in patients with tumoral calcinosis. II. Determine whether calcitonin reduces or prevents tumor recurrence. III. Determine whether hyperphosphatemia abolishes the normal circadian pattern of serum phosphorus. IV. Determine how repetitive calcitonin administration alters the biochemical markers of bone metabolism in osteopenic patients with tumoral calcinosis.
NCT00004358 Phase II Study of Calcitonin for Tumoral Calcinosis Completed National Center for Research Resources (NCRR) Phase 2 OBJECTIVES: I. Determine whether intermittent, long-term, subcutaneous administration of calcitonin increases phosphaturia, reduces hyperphosphatemia, and increases intact parathyroid hormone levels in patients with tumoral calcinosis. II. Determine whether calcitonin reduces or prevents tumor recurrence. III. Determine whether hyperphosphatemia abolishes the normal circadian pattern of serum phosphorus. IV. Determine how repetitive calcitonin administration alters the biochemical markers of bone metabolism in osteopenic patients with tumoral calcinosis.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Ondansetron

Condition Name

Condition Name for Ondansetron
Intervention Trials
Postoperative Nausea and Vomiting 45
Nausea 32
Vomiting 30
Healthy 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ondansetron
Intervention Trials
Vomiting 136
Nausea 113
Postoperative Nausea and Vomiting 69
Pain, Postoperative 33
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ondansetron

Trials by Country

Trials by Country for Ondansetron
Location Trials
United States 459
Canada 58
Italy 36
Germany 23
United Kingdom 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ondansetron
Location Trials
Texas 54
California 28
New York 28
North Carolina 24
Ohio 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ondansetron

Clinical Trial Phase

Clinical Trial Phase for Ondansetron
Clinical Trial Phase Trials
Phase 4 109
Phase 3 57
Phase 2/Phase 3 9
[disabled in preview] 86
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ondansetron
Clinical Trial Phase Trials
Completed 206
Recruiting 78
Not yet recruiting 44
[disabled in preview] 45
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ondansetron

Sponsor Name

Sponsor Name for Ondansetron
Sponsor Trials
Merck Sharp & Dohme Corp. 21
M.D. Anderson Cancer Center 18
GlaxoSmithKline 14
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ondansetron
Sponsor Trials
Other 419
Industry 117
NIH 34
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
US Army
Teva
Citi
AstraZeneca
Medtronic
Merck
Cantor Fitzgerald
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.